Pharmaceutical Stocks To Watch Now - August 23rd
Market Beat·- MarketBeat identified seven pharmaceutical stocks with the highest dollar trading volume to watch, including Eli Lilly, Merck, Johnson & Johnson, AbbVie, McKesson, Abbott Laboratories, and Pfizer. - These publicly traded companies engage in researching, developing, manufacturing, and selling medicines and healthcare products worldwide. - While offering growth potential from successful drug launches, these stocks also carry inherent risks such as clinical trial failures and regulatory decisions.Is Pfizer (PFE) Stock Too Pricey for Its Earnings Outlook?
Simplywall·- Pfizer trades at a P/E of 36.9 x, exceeding both the broader pharmaceutical industry average of 16.8 x and a tailored fair P/E ratio of 24.7 x. - While pipeline advancements and vaccine progress support market sentiment, risks such as patent cliffs and legal challenges remain. - The current valuation suggests the recent share price recovery has already priced in optimistic future earnings expectations.Vise Technologies Inc. Purchases 96,548 Shares of Pfizer Inc. $PFE
Market Beat·- Vise Technologies Inc. increased its holdings in Pfizer Inc. by 44.4% during the 2nd quarter, purchasing an additional 96,548 shares to own a total of 314,153 shares valued at $7,565,000. - Pfizer reported quarterly earnings of $0.77 per share with revenue reaching $15.03 billion, outperforming analysts' consensus estimates. - The company faces mixed market conditions, including recent clinical pipeline advancements, ongoing legal liabilities, and an average analyst rating of Hold with a target price of $28.28.Wealthfront Advisers LLC Reduces Position in Pfizer Inc. $PFE
Market Beat·- Wealthfront Advisers LLC reduced its holdings in Pfizer Inc. by 18.4% in the second quarter, retaining 672,665 shares valued at $16,198,000. - Pfizer recently reported a quarterly earnings per share of $0.77 and revenue of $15.03 billion, outperforming analysts' consensus estimates. - Institutional investors and analysts continue to monitor Pfizer amid ongoing clinical pipeline updates, dividend declarations, and patent cliff challenges.Prediction: This Is Where Pfizer Stock Will Be in 2030
Motley Fool·- Pfizer faces significant revenue pressure due to upcoming patent expirations for key drugs like Ibrance, Xtandi, and Eliquis between 2027 and 2028. - Despite investor concerns and a 2025 setback in developing an internal GLP-1 candidate, the company has actively acquired new assets and advanced its pipeline. - Pfizer is projected to enter a revenue recovery mode driven by high-single-digit growth from new drugs after 2028, despite ongoing patent expiration cycles.